TICKERNOMICS Sign up
Last Update: 2024-12-27 15:24:34
ARTIVION INC. ( AORT ) https://artivion.com
29.34USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
AORT
61.03%
SPY
32.66%
AORT
45.61%
SPY
108.59%
AORT
9.72%
SPY
302.52%
AORT
162.42%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1227.70
1490.01
0.13
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1442.66
3.19
4.03
1.26
0.00
23.19
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
4.58
63.70
16.60
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.7232
8.14
5.61
1.74
Other Earnings and Cash Flow Stats:
ARTIVION INC. ( AORT ) Net Income TTM ($MM) is -0.85
ARTIVION INC. ( AORT ) Operating Income TTM ($MM) is 39.38
ARTIVION INC. ( AORT ) Owners' Earnings Annual ($MM) is 0.00
ARTIVION INC. ( AORT ) Current Price to Owners' Earnings ratio is 0.00
ARTIVION INC. ( AORT ) EBITDA TTM ($MM) is 62.92
ARTIVION INC. ( AORT ) EBITDA Margin is 16.60%
Capital Allocation:
ARTIVION INC. ( AORT ) has paid 0.00 dividends per share and bought back -0.963 million shares in the past 12 months
ARTIVION INC. ( AORT ) has reduced its debt by 42.962 million USD in the last 12 months
Capital Structure:
ARTIVION INC. ( AORT ) Interest-bearing Debt ($MM) as of last quarter is 318
ARTIVION INC. ( AORT ) Annual Working Capital Investments ($MM) are 0
ARTIVION INC. ( AORT ) Book Value ($MM) as of last quarter is 304
ARTIVION INC. ( AORT ) Debt/Capital as of last quarter is 104%
Other Balance Sheet Stats:
ARTIVION INC. ( AORT ) has 56 million in cash on hand as of last quarter
ARTIVION INC. ( AORT ) has 152 million of liabilities due within 12 months, and long term debt 313 as of last quarter
ARTIVION INC. ( AORT ) has 41 common shares outstanding as of last quarter
ARTIVION INC. ( AORT ) has 0 million USD of preferred stock value
Academic Scores:
ARTIVION INC. ( AORT ) Altman Z-Score is 2.25 as of last quarter
ARTIVION INC. ( AORT ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
ARTIVION INC. ( AORT ) largest shareholder is owning shares at 0.00 ($MM) value
Holloway Jean F(an insider) Sold 4035 shares of ARTIVION INC. ( AORT ) for the amount of $121050.00 on 2024-12-11
5.51% of ARTIVION INC. ( AORT ) is held by insiders, and 85.58% is held by institutions
ARTIVION INC. ( AORT ) went public on 1993-02-12
Other ARTIVION INC. ( AORT ) financial metrics:
FCF:13.55
Unlevered Free Cash Flow:0.00
EPS:-0.22
Operating Margin:4.58
Gross Profit Margin:63.70
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-3.00
Beta:1.74
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About ARTIVION INC. ( AORT ) :
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.